Geraldine Goss

1.2k total citations
24 papers, 819 citations indexed

About

Geraldine Goss is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Obstetrics and Gynecology. According to data from OpenAlex, Geraldine Goss has authored 24 papers receiving a total of 819 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Oncology, 10 papers in Pulmonary and Respiratory Medicine and 7 papers in Obstetrics and Gynecology. Recurrent topics in Geraldine Goss's work include Endometrial and Cervical Cancer Treatments (7 papers), Lung Cancer Treatments and Mutations (6 papers) and Ovarian cancer diagnosis and treatment (5 papers). Geraldine Goss is often cited by papers focused on Endometrial and Cervical Cancer Treatments (7 papers), Lung Cancer Treatments and Mutations (6 papers) and Ovarian cancer diagnosis and treatment (5 papers). Geraldine Goss collaborates with scholars based in Australia, United States and South Korea. Geraldine Goss's co-authors include David C. Harmon, George D. Demetri, David P. Ryan, Judith Manola, José Jimeno, Michael V. Seiden, Robert G. Maki, Thomas A. Puchalski, C. Guzmán and Rocio García‐Carbonero and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Clinical Cancer Research.

In The Last Decade

Geraldine Goss

21 papers receiving 798 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Geraldine Goss Australia	13	494	452	157	153	141	24	819
Youn Choi Park United States	8	617 1.2×	548 1.2×	103 0.7×	183 1.2×	199 1.4×	13	1.0k
Maristella Saponara Italy	20	640 1.3×	255 0.6×	62 0.4×	94 0.6×	111 0.8×	70	1.2k
Anne‐Claire Hardy‐Bessard France	16	206 0.4×	640 1.4×	129 0.8×	74 0.5×	43 0.3×	59	961
J Chauvergne France	16	208 0.4×	353 0.8×	166 1.1×	228 1.5×	55 0.4×	107	833
E. Sandberg Denmark	10	163 0.3×	382 0.8×	78 0.5×	75 0.5×	58 0.4×	17	749
Maria Marples United Kingdom	10	357 0.7×	512 1.1×	45 0.3×	69 0.5×	104 0.7×	31	722
I. Ray-Coquard France	9	437 0.9×	352 0.8×	25 0.2×	221 1.4×	95 0.7×	28	712
Andreas duBois Germany	9	105 0.2×	291 0.6×	125 0.8×	93 0.6×	43 0.3×	15	713
Dirk Elling Germany	16	115 0.2×	303 0.7×	94 0.6×	65 0.4×	32 0.2×	51	656
J. Fra Spain	12	528 1.1×	649 1.4×	33 0.2×	90 0.6×	108 0.8×	40	907

Countries citing papers authored by Geraldine Goss

Since Specialization

Citations

This map shows the geographic impact of Geraldine Goss's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Geraldine Goss with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Geraldine Goss more than expected).

Fields of papers citing papers by Geraldine Goss

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Geraldine Goss. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Geraldine Goss. The network helps show where Geraldine Goss may publish in the future.

Co-authorship network of co-authors of Geraldine Goss

This figure shows the co-authorship network connecting the top 25 collaborators of Geraldine Goss. A scholar is included among the top collaborators of Geraldine Goss based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Geraldine Goss. Geraldine Goss is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Ngoi, Natalie Y.L., Chel Hun Choi, Diana Lim, et al.. (2025). Durvalumab versus Physician’s Choice Chemotherapy in Recurrent Ovarian Clear Cell Adenocarcinoma (MOCCA/APGOT-OV2/GCGS-OV3): A Multicenter, Randomized, Phase 2 Trial. Clinical Cancer Research. 31(18). 3907–3915. 2 indexed citations

Goss, Geraldine, Gail Darling, Virginie Westeel, et al.. (2024). LBA48 CCTG BR.31: A global, double-blind placebo-controlled, randomized phase III study of adjuvant durvalumab in completely resected non-small cell lung cancer (NSCLC). Annals of Oncology. 35. S1238–S1238. 17 indexed citations

Ananda, Sumitra, Yuxuan Wang, Wei Hong, et al.. (2023). Circulating tumor DNA (ctDNA) as a marker of residual disease and recurrence in resected stage I-IV epithelial ovarian cancer (EOC).. Journal of Clinical Oncology. 41(16_suppl). 5553–5553. 2 indexed citations

Smith, Deborah S., Kristy Robledo, Sonia Yip, et al.. (2022). Results of PD-L1 Analysis of Women Treated with Durvalumab in Advanced Endometrial Carcinoma (PHAEDRA). Cancers. 15(1). 254–254. 1 indexed citations

Tan, David S.P., Chel Hun Choi, Natalie Y.L. Ngoi, et al.. (2022). A multicenter phase II randomized trial of durvalumab (D) versus physician’s choice chemotherapy (PCC) in patients (pts) with recurrent ovarian clear cell adenocarcinoma (MOCCA/APGOT-OV2/GCGS-OV3).. Journal of Clinical Oncology. 40(16_suppl). 5565–5565. 17 indexed citations

Goss, Geraldine, et al.. (2021). Abstract PS13-36: Prevention of chemotherapy-induced alopecia: A prospective study in breast and ovarian cancer patients. Cancer Research. 81(4_Supplement). PS13–36.

Antill, Yoland, Peey‐Sei Kok, Kristy Robledo, et al.. (2021). Clinical activity of durvalumab for patients with advanced mismatch repair-deficient and repair-proficient endometrial cancer. A nonrandomized phase 2 clinical trial. Journal for ImmunoTherapy of Cancer. 9(6). e002255–e002255. 80 indexed citations

Smith, Deborah S., Kristy Robledo, Sonia Yip, et al.. (2021). Tumor-associated immune cells and progression-free survival in advanced endometrial cancer (EC), results from the PHAEDRA trial (ANZGOG 1601).. Journal of Clinical Oncology. 39(15_suppl). 5584–5584.

Hernández, M., Benjamin Besse, Mark M. Awad, et al.. (2021). P16.07 Immuno-Modulatory Effects of Ceralasertib in Combination with Durvalumab in NSCLC with Progression on Anti-PD(L)1 Treatment (HUDSON). Journal of Thoracic Oncology. 16(3). S350–S351. 2 indexed citations

10.

Ngoi, Natalie Y.L., Valerie Heong, Samuel G.W. Ow, et al.. (2020). A multicenter phase II randomized trial of durvalumab (MEDI-4736) versus physician’s choice chemotherapy in recurrent ovarian clear cell adenocarcinoma (MOCCA). International Journal of Gynecological Cancer. 30(8). 1239–1242. 16 indexed citations

11.

Antill, Yoland, Peey‐Sei Kok, Martin R. Stockler, et al.. (2019). Updated results of activity of durvalumab in advanced endometrial cancer (AEC) according to mismatch repair (MMR) status: The phase II PHAEDRA trial (ANZGOG1601). Annals of Oncology. 30. ix192–ix192. 20 indexed citations

12.

Blinman, Prunella, Linda Mileshkin, Pearly Khaw, et al.. (2016). Patients’ and clinicians’ preferences for adjuvant chemotherapy in endometrial cancer: an ANZGOG substudy of the PORTEC-3 intergroup randomised trial. British Journal of Cancer. 115(10). 1179–1185. 15 indexed citations

13.

Jordan, Susan J., Christopher Steer, Anna DeFazio, et al.. (2013). Patterns of chemotherapy treatment for women with invasive epithelial ovarian cancer – A population-based study. Gynecologic Oncology. 129(2). 310–317. 30 indexed citations

14.

Jonker, Derek J., Scott A. Laurie, Justin Call, et al.. (2008). Sunitinib (SU) in combination with pemetrexed (P) in patients (pts) with advanced solid malignancies: A phase I dose escalation study. Journal of Clinical Oncology. 26(15_suppl). 3566–3566. 5 indexed citations

15.

García‐Carbonero, Rocio, Jeffrey G. Supko, Robert G. Maki, et al.. (2005). Ecteinascidin-743 (ET-743) for Chemotherapy-Naive Patients With Advanced Soft Tissue Sarcomas: Multicenter Phase II and Pharmacokinetic Study. Journal of Clinical Oncology. 23(24). 5484–5492. 154 indexed citations

16.

García‐Carbonero, Rocio, Judith Manola, Michael V. Seiden, et al.. (2004). Phase II and Pharmacokinetic Study of Ecteinascidin 743 in Patients With Progressive Sarcomas of Soft Tissues Refractory to Chemotherapy. Journal of Clinical Oncology. 22(8). 1480–1490. 250 indexed citations

17.

Heymach, John V., Jayesh Desai, Judith Manola, et al.. (2004). Phase II Study of the Antiangiogenic Agent SU5416 in Patients with Advanced Soft Tissue Sarcomas. Clinical Cancer Research. 10(17). 5732–5740. 84 indexed citations

18.

Goss, Geraldine & George D. Demetri. (2000). Medical management of unresectable, recurrent low-grade retroperitoneal liposarcoma: integration of cytotoxic and non-cytotoxic therapies into multimodality care. Surgical Oncology. 9(2). 53–59. 14 indexed citations

19.

Shepherd, Frances A., Yvon Cormier, R. Burkes, et al.. (1997). Phase II trial of gemcitabine and weekly cisplatin for advanced non-small cell lung cancer.. PubMed. 24(3 Suppl 8). S8–27. 55 indexed citations

20.

Evans, William K., Frances A. Shepherd, Diane Logan, et al.. (1994). VP-16, ifosfamide and cisplatin (VIP) for extensive small cell lung cancer. European Journal of Cancer. 30(3). 299–303. 10 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact